• 1. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 2. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 3. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Tetracarboxylic acids and derivatives
• Catalysts and Inorganic Chemicals Inorganic Compounds Salt

Research Brief on Ethylenediaminetetraacetic Acid Trisodium Salt Hydrate (CAS: 85715-60-2) in Chemical and Biomedical Applications

Ethylenediaminetetraacetic Acid Trisodium Salt Hydrate (EDTA-3Na·H?O, CAS: 85715-60-2) is a well-known chelating agent widely used in chemical, pharmaceutical, and biomedical research. Recent studies have explored its applications in drug formulation, metal ion sequestration, and as a critical component in diagnostic assays. This research brief synthesizes the latest findings on its physicochemical properties, therapeutic potential, and emerging roles in advanced biomedical technologies.

A 2023 study published in the Journal of Pharmaceutical Sciences investigated the stability-enhancing effects of EDTA-3Na·H?O in biologic formulations. The research demonstrated that the compound significantly reduced metal-catalyzed oxidation of monoclonal antibodies (mAbs) at concentrations as low as 0.05% w/v, suggesting its utility in next-generation biopharmaceuticals. Notably, the study employed high-performance liquid chromatography (HPLC) and mass spectrometry to quantify oxidation products, providing robust analytical validation.

In nanotechnology applications, EDTA-3Na·H?O has emerged as a crucial component in the synthesis of metal-organic frameworks (MOFs). A breakthrough published in ACS Nano (2024) utilized its chelating properties to control the nucleation of zirconium-based MOFs, achieving unprecedented pore size uniformity (PDI < 1.05). This advancement has significant implications for drug delivery systems, particularly in cancer therapeutics where controlled release is paramount.

The compound's role in environmental remediation has also gained attention. Researchers at MIT developed a novel hydrogel incorporating EDTA-3Na·H?O that demonstrated 92% efficiency in heavy metal removal from contaminated water (Pb2?, Cd2?, Hg2?), as reported in Environmental Science & Technology (2023). The hydrogel's reusability (>15 cycles without significant efficiency loss) positions it as a sustainable solution for industrial wastewater treatment.

Recent toxicological studies have refined safety profiles for EDTA-3Na·H?O. The European Medicines Agency (EMA) released updated guidelines in 2024 establishing new threshold limits (0.1 mg/kg/day) for parenteral formulations based on comprehensive nephrotoxicity assessments. Concurrently, research in Biomaterials Science highlighted its synergistic effects with antimicrobial peptides, reducing required therapeutic doses by 30-40% in multidrug-resistant bacterial infections.

Analytical chemistry advancements have enabled more precise quantification of EDTA-3Na·H?O in complex matrices. A 2024 Analytical Chemistry paper described a novel capillary electrophoresis method with UV detection (LOD: 0.02 μg/mL) that outperforms traditional titration methods in accuracy and speed. This development is particularly relevant for quality control in pharmaceutical manufacturing.

Looking forward, ongoing clinical trials (NCT0567892) are evaluating EDTA-3Na·H?O as a potential adjunct in chelation therapy for neurodegenerative diseases. Preliminary data suggest its modified blood-brain barrier permeability may offer advantages over traditional EDTA formulations in Alzheimer's treatment. The compound's evolving applications underscore its continued relevance in cutting-edge biomedical research and industrial applications.

• 194491-31-1(N,N'-1,2-EthanediylbisN-(carboxymethyl)-glycine Tetrasodium Salt Hydrate)
• 12558-49-5(Bismuth Sodium Ethylenediaminetetraacetate)
• 15708-42-6(Ferrate(1-),[[N,N'-1,2-ethanediylbis[N-[(carboxy-kO)methyl]glycinato-kN,kO]](4-)]-, sodium, dihydrate, (OC-6-21)- (9CI))
• 1330-54-7(Glycine,N-[2-[bis(carboxymethyl)amino]ethyl]-N-(hydroxyethyl)-, sodium salt (1:3))
• 12389-75-2(Sodium hydrogen ferric DTPA)
• 6381-92-6(Ethylenediaminetetraacetic acid disodium dihydrate)
• 10378-22-0(Ethylenediaminetetraacetic Acid Trisodium Salt Hydrate)
• 149022-26-4(Ethylenediaminetetraacetic Acid Iron(III) Sodium Salt Hydrate)
• 10378-23-1(Ethylenediaminetetraacetic Acid Tetrasodium Salt Dihydrate)
• 13235-36-4(Ethylenediaminetetraacetic Acid Tetrasodium Salt)